Biopharmaceutical Study of an Injectable Dosage Form of the New Antiaggregant Substance 3-Methyl-8-(Piperazin-1-yl)-7-(Thietan-3-yl)-1-Ethyl-1H-Purine-2,6(3H,7H)-Dione Hydrochloride

Smirnova, L. A.; Spasov, A. A.; Khaliullin, F. A.; Kucheryavenko, A. F.; Ryabukha, A. F.; Abramov, O. K.

Biopharmaceutical Study of an Injectable Dosage Form of the New Antiaggregant Substance 3-Methyl-8-(Piperazin-1-yl)-7-(Thietan-3-yl)-1-Ethyl-1H-Purine-2,6(3H,7H)-Dione Hydrochloride

Smirnova, L. A., Spasov, A. A., Khaliullin, F. A., Kucheryavenko, A. F., Ryabukha, A. F., Abramov, O. K.

Publication date: 2021

Abstract:

The pharmacokinetic parameters of the parent substance and the injectable dosage form of the new antiplatelet drug 3-methyl-8-(piperazin-1-yl)-7-(thietan-3-yl)-1-ethyl-1H-purine-2,6(3H,7H)-dione hydrochloride in rabbit blood plasma upon intravenous administration were compared and analyzed. The relative bioavailability coefficient was determined to be 0.97.

Keywords:
3-methyl-8-(piperazin-1-yl)-7-(thietan-3-yl)-1-ethyl-1H-purine-2,6(3H,7H)-dione hydrochloride, absolute bioavailability, pharmacokinetics, Scopus

Издатель: Springer

Тип: Article

Biopharmaceutical Study of an Injectable Dosage Form of the New Antiaggregant Substance 3-Methyl-8-(Piperazin-1-yl)-7-(Thietan-3-yl)-1-Ethyl-1H-Purine-2,6(3H,7H)-Dione Hydrochloride

Фасеты

Оппонент

Научный руководитель

Авторы

Ключевые слова

Год